Clinical trial
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic…
NCT00391079 · GW Pharmaceuticals Ltd, Industry · Completed
Key facts
| NCT number | NCT00391079 |
|---|---|
| Title | Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS |
| Official title | A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis |
| Lead sponsor | GW Pharmaceuticals Ltd, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Sativex, Placebo |
| Enrollment | 339 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 23, 2006 |
| Last update posted | Jun 24, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: